Annonce • May 26
MustGrow Biologics Corp. announced that it expects to receive CAD 2 million in funding MustGrow Biologics Corp. announced a non-brokered private placement to issue 4,000,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 2,000,000 on May 25, 2026. Each unit will consist of: one common share and one common share purchase warrant. Each warrant will be exercisable for a period of 60 months from the closing date and will entitle the holder thereof to purchase one additional common share at an exercise price of CAD 0.70 per warrant share. It is expected that closing of the LIFE offering will take place on or about June 11, 2026, or such other dates as may be determined the company. Closing of the LIFE offering is subject to certain conditions, including, but not limited to, receipt of all necessary approvals, including the approval of the TSX-V. As consideration for services, certain eligible finders may receive aggregate cash fees equal up to 6% of the gross proceeds of the LIFE offering from investors introduced to the company by the finders; and non-transferable common share purchase warrants representing up to 6.0 per cent of the aggregate number of units sold to investors introduced to the company by the finders. Each finder's warrant will entitle its holder to purchase one common share at a price of CAD 0.70 cents per finder's warrant share for a 60-month period. The finders' warrants and any finders' warrant shares issuable upon exercise thereof will be subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws. Subject to the rules and policies of the TSX Venture Exchange, the securities issuable from the sale of units to Canadian resident subscribers will not be subject to a hold period under applicable Canadian securities laws. Insiders and certain consultants that participate in the LIFE offering would be subject to a four-month hold period pursuant to applicable policies of the TSX-V. Annonce • Apr 28
MustGrow Biologics Corp., Annual General Meeting, Jun 25, 2026 MustGrow Biologics Corp., Annual General Meeting, Jun 25, 2026. Annonce • Jan 24
MustGrow Biologics Corp. announced that it has received CAD 2 million in funding On January 23, 2026. MustGrow Biologics Corp. announces that it has closed the transaction. It has issued 4,000,000 units at a price of 0.50 per unit for gross proceeds of CAD 2,000,000. As consideration for services, certain eligible finders received an aggregate cash fee equal to CAD 105,000, being 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by such finders and 210,000 non-transferable common share purchase warrants. Annonce • Jan 09
MustGrow Biologics Corp. announced that it expects to receive CAD 2 million in funding MustGrow Biologics Corp announced a non brokered private placement to issue 4,000,000 units at a price of CAD 0.5 per unit for aggregate gross proceeds of CAD 2,000,000 on January 8, 2026. Each Unit will consist of one common share of the Company and one common share purchase warrant. Each whole Warrant will be exercisable for a period of 60 months from the Closing Date and will entitle the holder thereof to purchase one additional Share at an exercise price of CAD 0.70 per Warrant Share. Insiders and certain consultants who participate in the LIFE Offering would be subject to a four-month hold period pursuant to applicable policies of the TSXV. The transaction is expected to close on January 22, 2026. The Units sold pursuant to the LIFE Offering will be offered in Canada pursuant to the listed issuer financing exemption from the prospectus requirement available under Part 5A of National Instrument 45-106 - Prospectus Exemptions. As consideration for services, certain eligible finders may receive an aggregate cash fee equal up to 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by the finder; and non-transferable common share purchase warrants representing up to 6.0% of the aggregate number of Shares forming part of the Units issued to investors introduced to the Company by the finder. Each Finder's Warrant will entitle its holder to purchase one Share at a price of CAD 0.70 per Share for a 60-month period. The Finder Warrants and any Finder Warrant Shares issuable upon exercise thereof will be subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws. It is anticipated that insiders of the Company may participate in the LIFE Offering, and any Units issued to insiders will be subject to a four-month hold period pursuant to applicable policies of the TSXV. The issuance of Units to any insiders will be considered a "related party transaction" within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions("MI 61-101"). Annonce • Aug 29
MustGrow Biologics Corp. announced that it has received CAD 2.141812 million in funding On August 29, 2025, MustGrow Biologics Corp closed the transaction. The company issued 3,059,731 units at a price of CAD 0.7 er unit for aggregate gross proceeds of CAD 2,141,811.7. The company paid to certain eligible finders, an aggregate cash fee equal to CAD 86,332.60, being 6% of the gross proceeds from the offering from investors introduced to the Company by such finders and 123,318 non-transferable common share purchase warrants representing 6% of the aggregate number of Shares forming part of the Units issued to investors introduced to the Company by the finders. Each Finder's Warrant will entitle its holder to purchase one share at a price of CAD 0.9 per share for a period of 60 months. The Finder Warrants and any Finder Warrant Shares issuable upon exercise thereof will be subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws. Annonce • Jul 31
MustGrow Biologics Corp. announced that it expects to receive CAD 3.000001 million in funding MustGrow Biologics Corp announced a non-brokered private placement to issue o 4,285,715 units of the Company at a price of CAD 0.7 per unit for aggregate gross proceeds of CAD 3,000,000.5 on July 30, 2025. Each Unit will consist of one Common share of the company and one common share purchase warrant. Each whole Warrant will be exercisable for a period of 60 months from the Closing Date and will entitle the holder thereof to purchase one additional Share at an exercise price of CAD 0.9 per Warrant Share. Insiders and certain consultants that participate in the LIFE Offering would be subject to a four-month hold period pursuant to applicable policies of the TSXV. The transaction is expected to close on or about August 21, 2025. As consideration for services, certain eligible finders may receive an aggregate cash fee equal up to 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by the finder; and non-transferable common share purchase warrants representing up to 6.0% of the aggregate number of Shares forming part of the Units issued to investors introduced to the Company by the finder. Each Finder's Warrant will entitle its holder to purchase one Share at a price of CAD 0.9 per Share for a 60-month period. The Finder Warrants and any Finder Warrant Shares issuable upon exercise thereof will be subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws. Annonce • Apr 29
MustGrow Biologics Corp., Annual General Meeting, Jun 26, 2025 MustGrow Biologics Corp., Annual General Meeting, Jun 26, 2025. Annonce • Jan 17
MustGrow Biologics Corp. announced that it has received CAD 2.585 million in funding On January 16, 2025, MustGrow Biologics Corp closed the transaction. The company issued 2,585 units at a price of CAD 1,000 per unit for the gross proceeds of CAD 2,585,000. In connection with the Private Placement, certain finders received an aggregate cash fee of CAD 67,200. Annonce • Jan 02
MustGrow Biologics Corp. (TSXV:MGRO) completed the acquisition of NexusBioAg from Univar Solutions Canada Ltd. MustGrow Biologics Corp. (TSXV:MGRO) signed a non-binding term-sheet to acquire NexusBioAg from Univar Solutions Canada Ltd on November 27, 2024. MustGrow Biologics Corp. (TSXV:MGRO) signed an agreement to acquire NexusBioAg from Univar Solutions Canada Ltd on December 31, 2024. MustGrow Biologics Corp. will pay deferred cash payment and contingent payments to be paid in 2025 and 2026, in each case subject to certain adjustments to be agreed to in the definitive transaction documents. The parties are targeting a closing on or about December 31, 2024.
The transaction is subject to approval by TSX Venture Exchange, approval of offer by MustGrow Biologics board of directors, consummation of due diligence investigation and definitive agreement.
MustGrow Biologics Corp. (TSXV:MGRO) completed the acquisition of NexusBioAg from Univar Solutions Canada Ltd on January 2, 2025. The consideration includes (i) a deferred cash payment of approximately $1.662 million subject to adjustment in accordance with the terms of the APA; and (ii) earn-out payments equal to a specified percentage amount of gross margin on certain itemized products sold by MGRO in 2025 and 2026.The TSX Venture
Exchange has conditionally approved the acquisition, subject to customary post-closing requirements. Annonce • Dec 12
MustGrow Biologics Corp. announced that it expects to receive CAD 2 million in funding MustGrow Biologics Corp. announced a non-brokered private placement of 2,000 units at a price of CAD 1,000 per unit for the gross proceeds of CAD 2,000,000 on December 11, 2024. Each unit will be comprised of: (i) CAD 1,000 principal amount of unsecured convertible debentures (the "debentures"); and (ii) 666 common share purchase warrants. Each debenture may, at the option of the holder: (i) be converted into common shares in the capital of the company (the "common shares") at price of CAD 1.50 per common share at any time; or (ii) paid in cash 60 months following the closing date (subject to certain acceleration and automatic conversion rights). Each warrant will be exercisable by the holder thereof to acquire one common share at a price of CAD 1.90 per common share for a period of 60 months following the closing date. The debentures will accrue interest at a rate of 8% per annum. Accrued interest shall be payable semi-annually in cash. The Debentures, the Warrants and any underlying Common Shares will be subject to a four month hold period from the Closing Date. The Private Placement is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSXV. The transaction is expected to close on January 10, 2025. Annonce • Sep 12
Mustgrow Biologics Corp. Receives Florida Registration for TerraSante Biofertility Product MustGrow Biologics Corp. announced receipt of the Florida Department of Agriculture and Consumer Services registration approval for its mustard plant-based TerraSanteTM, an organic biofertility product. The Florida organic certification is included under MustGrow's existing Organic OMRI Listed®? certifications in Arizona, Idaho, Oregon, and Washington State. MustGrow's Florida registration and organic certification is a key pillar in the commercialization strategy with BioAg Product Strategies. In addition to Florida, and recently-awarded Arizona, Idaho, California, Oregon, and Washington State, MustGrow expects to continue its efforts towards further state-level registrations in other pertinent U.S. states. In 2022, Florida ranked first in the U.S. in the production value of bell peppers (USD 262 million), floriculture (USD 1.16 billion), foliage plants for indoor use (USD 481 million), Valencia oranges (USD 289 million), grapefruit (USD 706 million), sugarcane (USD 752 million), fresh market tomatoes (USD 323 million) and watermelons (USD 216 million). TerraSanteTM for Soil and Ecological Health. MustGrow's soil amendment and biofertility development programs focus on soil and soil microbiome health, nutrient and water use efficiencies, and plant yields. Soil is a farmer's most valuable asset, and MustGrow's mustard plant-based technologies are being developed with the intention to improve not only the health of the soil, but also the surrounding ecological environment. As an organic biofertilizer in soluble mixable form, TerraSanteTM contains nutritious plant proteins and carbohydrates that feed the soil and soil microbes, potentially improving beneficial microbial activity and ensuring long-term sustainable soil health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSanteTM has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing. Annonce • May 09
Mustgrow Biologics Corp. Receives California Department of Food Agriculture Registration Approval MustGrow Biologics Corp. announced receipt of the California Department of Food Agriculture registration approval for its mustard plant-based TerraSante, an organic biofertility product. MustGrow's TerraSante has also received organic certification from California's Organic Input Material (OIM) Program, a specific California requirement beyond MustGrow's existing Organic OMRI Listed® certifications in Oregon and Washington State. TerraSante product sales are now authorized to commence in California. The registration and certification are an important step in MustGrow's commercialization strategy with BioAg Product Strategies to develop and commercialize MustGrow's soil amendment and biofertility technologies, including TerraSante. In addition to California, and recently-awarded Oregon and Washington State, MustGrow expects to continue its efforts towards further state-level registrations in other pertinent U.S. states. MustGrow's TerraSante product complements the Company's existing biocontrol programs in preplant soil fumigation, postharvest food preservation, and bioherbicide, which are currently under development with four global partners: Bayer, Sumitomo Corporation, Janssen PMP, and NexusBioAg. MustGrow's soil amendment and biofertility development programs focus on soil microbiome health, nutrient and water use efficiencies, and plant yields. Soil is a farmer's most valuable asset, and MustGrow's mustard plant-based technologies are being developed with the intention to improve not only the health of the soil, but also the surrounding ecological environment. As an organic biofertilizer in soluble mixable form, TerraSante contains nutritious plant proteins and carbohydrates that feed soil microbes, potentially improving beneficial microbial activity and ensuring long-term sustainable soil health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSante has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing. Reported Earnings • Apr 24
Full year 2023 earnings released: CA$0.014 loss per share (vs CA$0.11 loss in FY 2022) Full year 2023 results: CA$0.014 loss per share (improved from CA$0.11 loss in FY 2022). Revenue: CA$4.71m (up CA$4.71m from FY 2022). Net loss: CA$676.9k (loss narrowed 88% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. New Risk • Jan 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 30% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (€48.9m market cap, or US$53.7m). Board Change • Jan 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Laura Westby was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Dec 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.9m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 30% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€37.0m market cap, or US$40.2m). Reported Earnings • Sep 03
First half 2023 earnings released: CA$0.045 loss per share (vs CA$0.05 loss in 1H 2022) First half 2023 results: CA$0.045 loss per share (improved from CA$0.05 loss in 1H 2022). Net loss: CA$2.25m (loss narrowed 7.5% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 60% per year, which means it is well ahead of earnings. New Risk • Jul 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (CA$5.0k revenue, or US$3.8k). Minor Risk Market cap is less than US$100m (€70.4m market cap, or US$76.9m). Annonce • Jun 15
MustGrow Biologics Corp. Completes Initial Commercial Production Run Via Contract Manufacturer MustGrow Biologics Corp. announce the successful initial commercial run-rate production of its mustard plant-based biocontrol liquid via a contract manufacturer. MustGrow believes this production milestone further validates the Company's commercialization strategy to initially utilize a third party contract manufacturer rather than construct its own capital-intensive pilot and/or commercial production facilities. The continuous production run-rate of the extract reached greater than the equivalent of 5,000 litres per day of MustGrow's mustard plant-based biocontrol liquid technology,which is estimated to equal approximately USD 25 million in annual grower level revenue. The production process created zero residual waste by generating a high protein byproduct ingredient for animal feed. Recent Insider Transactions • Dec 10
Independent Director recently sold €70k worth of stock On the 7th of December, Brian Quigley sold around 30k shares on-market at roughly €2.35 per share. This transaction amounted to 7.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Breakeven Date Change • Apr 28
Forecast to breakeven in 2023 The analyst covering MustGrow Biologics expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$1.22m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Is New 90 Day High Low • Jan 19
New 90-day high: €1.49 The company is up 531% from its price of €0.24 on 21 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. Is New 90 Day High Low • Dec 29
New 90-day high: €0.73 The company is up 187% from its price of €0.25 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 6.0% over the same period. Recent Insider Transactions • Dec 24
COO & Director recently sold €55k worth of stock On the 22nd of December, Colin Bletsky sold around 82k shares on-market at roughly €0.67 per share. This was the largest sale by an insider in the last 3 months. Colin has been a seller over the last 12 months, reducing personal holdings by €46k. Is New 90 Day High Low • Dec 09
New 90-day high: €0.61 The company is up 136% from its price of €0.26 on 10 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. Is New 90 Day High Low • Nov 20
New 90-day high: €0.30 The company is up 6.0% from its price of €0.29 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. 